Overview

A Phase 2 Extension Study of Study GCS-100-CS-4002

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and tolerability of extended dosing of GCS-100 in patients with CKD.
Phase:
Phase 2
Details
Lead Sponsor:
La Jolla Pharmaceutical Company